Eli Lilly hits record high: Here’s what investors need to know

Jared Holz, Mizuho Securities healthcare strategist, joins ‘Squawk on the Street’ to discuss why supply imbalances could boost Eli Lilly’s future earnings reports, if clients are asking about the company’s valuation, and if there will be capacity constraints coming for healthcare companies.